Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Rhea-AI Summary
Scienture (NASDAQ: SCNX) secured $11.0 million in non-dilutive debt financing via two promissory notes: an $8.42 million unsubordinated note and a $3.0 million secured note. Proceeds will fund commercialization of FDA-approved Arbli and REZENOPY and advance multiple R&D programs; the company reiterated an expectation to reach profitability in 2027.
AI-generated analysis. Not financial advice.
Positive
- $11.0M non-dilutive financing raised
- Capital earmarked to commercialize Arbli and REZENOPY
- Proceeds to advance multiple clinical-stage R&D programs
Negative
- Financing increases consolidated debt by $11.0M
- Includes a $3.0M secured promissory note that may encumber assets
News Market Reaction – SCNX
On the day this news was published, SCNX gained 8.64%, reflecting a notable positive market reaction. Argus tracked a peak move of +18.2% during that session. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $17.26M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SCNX is modestly higher (+0.13%) with slightly elevated volume, while only one tracked peer (HKPD) showed upside momentum and others were mixed. This points to a stock-specific reaction to the non-dilutive debt financing rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Patent exclusivity | Positive | +0.1% | New U.S. patent extends ARBLI™ market protection into 2041. |
| Apr 15 | Nasdaq compliance | Neutral | +16.7% | Nasdaq grants 180-day extension to regain $1.00 bid compliance. |
| Apr 06 | Shareholder update | Positive | +10.3% | Annual update highlights 216% revenue growth and commercialization progress. |
| Mar 30 | Earnings results | Negative | -42.2% | 2025 results show higher revenue but large net loss and impairment. |
| Mar 11 | Access expansion | Positive | +19.5% | GPO deals give REZENOPY™ access to over 5,000 institutions. |
Recent positive corporate and commercial updates have often coincided with positive price reactions, though the 2025 earnings release drew a sharp negative move.
Over the last few months, Scienture has reported major commercial and financial milestones, including strong revenue growth, expanded access for REZENOPY™, and new patent protection for ARBLI™. Regulatory updates around Nasdaq listing compliance and annual results highlighted both growth and substantial losses. Today’s non-dilutive debt financing builds on this trajectory by adding capital to support commercialization and pipeline development, following recent 8-K disclosure of the note terms and an updated investor presentation.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-08-01, currently noted as not effective, with at least 4 prior takedowns via 424B5 filings. This structure provides flexibility for future registered capital raises if and when it becomes effective.
Market Pulse Summary
The stock moved +8.6% in the session following this news. A strong positive reaction aligns with the company’s pattern of responding well to financing and commercialization milestones, as seen after prior Nasdaq and access updates. The $11 million non-dilutive debt adds runway for ARBLI™ and REZENOPY™ launches and pipeline work. However, existing debt terms, prior equity usage under the S-3, and past large losses suggest investors should monitor balance-sheet leverage and future capital decisions closely.
Key Terms
non-dilutive debt financing financial
note purchase agreement financial
promissory note financial
secured promissory note financial
form 8-k regulatory
fda-approved regulatory
opioid antagonist medical
angiotensin ii receptor blocker medical
AI-generated analysis. Not financial advice.
Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatment
Financing also drives early- and late-stage clinical execution of diverse pipeline spanning multiple therapeutic areas
COMMACK, NY, May 07, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has secured
“This non-dilutive financing provides us with additional capital to execute on our critical strategic initiatives, including the continued scaling of our commercial efforts for Arbli™, REZENOPY™, and the ongoing advancement of our opportunistic drug development pipeline,” said Narasimhan Mani, President and Co-CEO of Scienture. “Moreover, the strengthening of our capital position through this financing will be a catalyst that will help carry us through to profitability, which we anticipate achieving in 2027.”
“With this capital in place, we are razor-focused on executing our operational milestones and fulfilling our mission to deliver enhanced value to patients and the healthcare systems across a broad range of therapeutic areas,” added Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We appreciate the support of our new and existing investors and their continued confidence in our ability to achieve sustained growth in the path ahead.”
Support for 2026 Commercial Launch Programs
Scienture intends to deploy the capital received from the financing to support commercialization and product launch activities of its two FDA-approved products, Arbli™ (losartan potassium) Oral Suspension, 10mg/mL for hypertension treatment and REZENOPY (naloxone HCl) Nasal Spray 10mg for the emergency treatment of opioid overdose.
In October 2025, Scienture announced the commercial availability of Arbli™, establishing it as the first and only FDA-approved ready-to-use liquid losartan formulation accessible through established pharmaceutical distribution channels across the United States. Losartan, an angiotensin II receptor blocker (ARB), is widely prescribed for the treatment of high blood pressure.
Scienture also entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. for the exclusive U.S. rights to commercialize REZENOPY, an opioid antagonist that was approved by the FDA in April 2024.
Advancement of Research and Development Pipeline
Scienture also intends to utilize proceeds from the non-dilutive financing to advance the clinical development of innovative product candidates in its diverse R&D portfolio. These include:
- SCN-104, a drug-device combination for the treatment of migraine.
- SCN-106, a potential biosimilar for thrombosis.
- SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic that is indicated for postsurgical local and regional analgesia.
Additional information on Scienture’s R&D pipeline is available at www.scienture.com/products.
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has three issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About REZENOPY™
REZENOPY™ (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
REZENOPY™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT SAFETY INFORMATION
REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.
Important Safety Information
- Contraindications: REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
- Warnings and Precautions:
- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
- Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
- Adverse Reactions: The following adverse reactions were observed in a REZENOPY™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
For complete product information, including Patient Information, please refer to the full Prescribing Information.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
